TargetMol

WT-1 A1

Product Code:
 
TAR-TP2478
Product Group:
 
Peptides
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TP2478-100mg100mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2478-500mg500mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
WT-1 A1 is an attractive target for immunotherapy in patients with pancreatic adenocarcinoma.
CAS:
852243-39-1
Molecular Weight:
1115.3
Purity:
0.98
SMILES:
C([C@H](CC1=CC=CC=C1)NC([C@@H](NC([C@H](CC2=CC=C(O)C=C2)N)=O)CCSC)=O)(=O)N3[C@H](C(N[C@H](C(N[C@H](C(=O)N4[C@H](C(N[C@@H](CC5=CC=C(O)C=C5)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)CCC4)C)=O)CC(N)=O)=O)CCC3

References

Terashima T, Mizukoshi E, Arai K, Yamashita T, Yoshida M, Ota H, Onishi I, Kayahara M, Ohtsubo K, Kagaya T, Honda M, Kaneko S. P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma. Cancer Immunol Immunother. 2014 May;63(5):479-89. doi: 10.1007/s00262-014-1529-8. Epub 2014 Mar 16. PubMed PMID: 24633336. Asma GE, van den Bergh RL, Vossen JM. Characterization of early lymphoid precursor cells in the human fetus using monoclonal antibodies and anti-terminal deoxynucleotidyl transferase. Clin Exp Immunol. 1986 May;64(2):356-63. PubMed PMID: 3742878; PubMed Central PMCID: PMC1542329. Akiyama Y, Oshita C, Kume A, Iizuka A, Miyata H, Komiyama M, Ashizawa T, Yagoto M, Abe Y, Mitsuya K, Watanabe R, Sugino T, Yamaguchi K, Nakasu Y. ?-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. BMC Cancer. 2012 Dec 27;12:623. doi: 10.1186/1471-2407-12-623. PubMed PMID: 23270484; PubMed Central PMCID: PMC3541167. Adkins WK, Barnard JW, Moore TM, Allison RC, Prasad VR, Taylor AE. Adenosine prevents PMA-induced lung injury via an A2 receptor mechanism. J Appl Physiol (1985). 1993 Mar;74(3):982-8. PubMed PMID: 8387073.